Clinic
Tunkhannock Hospital Company LLC
Tunkhannock Hospital Company LLC was paid $275K by Medicaid between Feb 2020 and Sep 2021, across 52 billing codes. Its largest line is 99284, emergency room visit (serious) — 20% of everything it billed.
33Billing provider infoTUNKHANNOCK HOSPITAL COMPANY LLC
TUNKHANNOCK, PA 18657
TUNKHANNOCK, PA 18657
33aNPI1518256726assigned 03/29/2011
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$275K
24GClaims13,239
24DCodes billed52
24AFirst – last monthFeb 2020 – Sep 2021
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Pennsylvania
Rank by total paid#35 of 119
Median peer was paid$57K
This provider vs. median4.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 2,405 | $55K | |
| 2021 | 10,834 | $220K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 676 | 637 | $54K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 929 | 885 | $49K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 8.8% | 760 | 731 | $24K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.4% | 191 | 184 | $20K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.7% | 162 | 162 | $13K |
| 80053 | Comprehensive metabolic panel | 4.5% | 1,254 | 1,175 | $12K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 3.1% | 304 | 299 | $9K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 209 | 201 | $7K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.6% | 281 | 266 | $7K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 117 | 112 | $7K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.4% | 1,333 | 1,221 | $7K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.4% | 308 | 303 | $7K |
40 more codes
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.9% | 476 | $5K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.9% | 30 | $5K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.6% | 530 | $4K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 41 | $4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.3% | 60 | $4K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 195 | $3K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.0% | 212 | $3K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 212 | $3K |
| 80061 | Lipid panel | <1% | 214 | $3K |
| 84703 | <1% | 237 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 274 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 169 | $2K |
| 84484 | <1% | 273 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 240 | $2K |
| 80305 | <1% | 119 | $1K | |
| 83690 | <1% | 291 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 175 | $1K |
| 81001 | <1% | 476 | $1K | |
| 84439 | <1% | 162 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 24 | $940.79 |
| 85027 | <1% | 148 | $933.00 | |
| 85610 | <1% | 298 | $905.44 | |
| 87040 | <1% | 68 | $768.60 | |
| 86618 | <1% | 31 | $743.92 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 99 | $621.46 |
| 36415 | Collection of venous blood by venipuncture | <1% | 499 | $568.00 |
| 83735 | <1% | 86 | $530.05 | |
| 83605 | <1% | 67 | $461.20 | |
| 85651 | <1% | 159 | $428.39 | |
| 84481 | <1% | 14 | $309.56 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 248 | $188.54 |
| 86140 | <1% | 64 | $177.60 | |
| 82150 | <1% | 41 | $177.25 | |
| 73610 | <1% | 12 | $161.03 | |
| 73630 | <1% | 12 | $106.86 | |
| 85378 | <1% | 12 | $92.67 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 205 | $88.31 |
| J2704 | Injection, propofol, 10 mg | <1% | 25 | $30.10 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 181 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 36 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.